FOLH1 and prostate carcinoma: Results from another study showed the feasibility of using poly(lactide-co-glycolide)-PEG, (PLGA-PEG), nanoparticles encapsulating EGCG, functionalized with a small organic molecule (prostate-specific membrane antigen (PSMA) inhibitor) on the surface to enhance ECGC delivery specifically to prostate cancer cells.